Idiopathic Pulmonary Fibrosis (IPF)

Trial Objective

GERD & IPFThe purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI). The study also will determine if stomach reflux or abnormal swallowing are associated with the progression of IPF.


New enrollment for this trial is temporarily paused

Who Can Participate

Individuals ages 40-95 who have been diagnosed with IPF may be eligible to participate.

Age: 40-95    Gender: Any Gender

Estimated Time Commitment

5 visits over a 6-month period, visits are every 3 months

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Melissa Schwab, Trial Coordinator

Melissa Schwab

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Boehringer Ingelheim

Principal Investigators

Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More